Limbix Spark Clinical Trial Strategy

2019

2020

2021

2022

2023

Phase I Feasibility Clinical Trial Start

Phase I Feasibility Clinical Trial Completed

Phase II RCT Start

Phase II RCT Completion

FDA Pivotal Trial Start

FDA Pivotal RCT Completion

Phase I Results

Significant reduction in adolescent depressive symptoms

PHQ-8 score

moderately severe

moderate

mild

20.00

17.50

15.00

12.50

10.00

7.50

5.00

Pre-Tx

Week 2

Week 3

Week 4

Week 5

Post-Tx

1 Month
Follow Up

Collaborate with Limbix

Interested in partnering for clinical research? Please contact: research@limbix.com